Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET-01 in Subjects With Lateral Canthal Lines
NCT03655691Phase 2Completed
- Sponsor
- Eirion Therapeutics
- Start
- Aug 2018
- Primary completion
- Nov 2018
- Modality
- CRISPR-Cas9, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ET-01 in lateral canthal rhytides (3 arms), sponsored by Eirion Therapeutics. Primary endpoint: Number of Participants With a Response Defined as Change in IGA-C Score by at Least 2 Ordinals From Baseline to Week 4. Started Aug 2018; status: completed.
02
Drugs
ET-01
03
Conditions
lateral canthal rhytides
Beyond the preview
Go deeper on NCT03655691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03655691.